Investigating taste, smell, and sensory functions in patients undergoing stem cell transplantation
Official title: Oral, Chemosensory and Trigeminal Functions in Allogeneic Hematopoietic Stem Cell Transplantation - a Prospective Cohort-study
Run by University of Oslo · NCT06003660 · Data updated 2026-11-12
This study is trying to see how stem cell transplants affect taste and smell in patients and how these changes might impact their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 70 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | University of Oslo Academic / other |
| Locations | 1 site (Oslo, Oslo) |
| Status | Recruiting |
| Started | August 10, 2023 |
| Main results expected | December 30, 2026 |
| Study ends | March 1, 2028 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT06003660 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients receiving myeloablative conditioning for a first-time allo-HSCT diagnosed with leukemia or myelodysplastic syndrome.
✕Probably not a fit
Patients with disorders affecting the oral cavity, those on medications impacting sensory functions, or individuals with chronic immune disorders or brain disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study aims to explore the effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on taste, smell, and trigeminal functions in patients. The research will assess various sensory functions using standardized tests, including smell and taste assessments, salivary flow measurements, and brain imaging to evaluate changes in relevant cortical regions. Participants will also complete questionnaires to evaluate their quality of life and nutritional status, with comparisons made to healthy controls to identify significant differences. The study seeks to understand the potential sensory dysfunctions that may arise post-transplantation.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for sensory dysfunctions in patients undergoing stem cell transplantation.
How similar studies have gone: While this specific approach is novel, similar studies have indicated that sensory dysfunction can occur in patients undergoing stem cell transplantation, suggesting a potential for meaningful insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • patients receiving myeloablative conditioning for a first-time allo-HSCT and diagnosed with either a leukemia or a myelodysplastic syndrome Exclusion Criteria: * disorders affecting the oral cavity including poor tooth-status * those using drugs affecting the gustatory/olfactory functions * those with brain disorders * those who have a chronic disorder affecting the immune system, have cancer or who are pregnant.
Where it's running
-
University of Oslo
Oslo, Oslo, Norway Recruiting
Study contacts
- Study coordinator: Per Ole Iversen, phd
- Email: p.o.iversen@medisin.uio.no
- Phone: +47 22 85 13 91
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant
This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.
-
Population PK-guided ATG Dosing in Haplo-HSCT
This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
-
Personalized ATG dosing in unrelated donor stem cell transplants
This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.
-
Hematologic cancer survivors after stem cell transplant try a personalized care plan
This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.
-
T-cell–guided letermovir stopping after allogeneic stem cell transplant
This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.